Sucampo Pharmaceuticals, Inc. SCMP reported adjusted earnings of 27 cents per share in the third quarter of 2017, beating the Zacks Consensus Estimate of 25 cents. However, reported earnings were down 10% from the year-ago figure of 30 cents.
Total revenue came in at $61.3 million, up 6% from the year-ago quarter, and surpassed the Zacks Consensus Estimate of $57.44 million, driven by higher Amitiza sales in the United States and Japan. Sucampo has a license, commercialization and supply agreement with Mylan N.V. MYL for marketing Amitiza in Japan.
Sucampo’s share price has decreased 29.2% year to date, while the industry lost 0.9%.
The Quarter in Detail
Product sales were $35.8 million, up 14% year over year. Product royalty revenues were $23 million, up 11% year over year.
Sales of Amitiza as reported by Takeda Pharmaceutical for royalty calculation purposes, in the United States were $115.2 million, up 6% due to strong marketing and selling, as well as growth in branded market. Takeda holds the global marketing rights for Amitiza outside Japan and China and pays royalties to Sucampo. As reported by Mylan, Amitizia sales increased 18% to $20.5 million in Japan. Unit volume increased 35%.
The company’s operational expense (R&D and S&GA) increased 4% from the year-ago period to $22.6 million due to inclusion of research & development expense related to Vtesse.
Developments
In July 2017, the company filed a supplemental new drug application (sNDA) with the FDA for label expansion of Amitizia to include pediatric patients (10-17 year of age) suffering from functional constipation. The sNDA was granted priority review with a decision expected on Jan 28, 2018.
Moreover, during the quarter, the FDA granted Fast-Track status to CPP-1X/sulindac, which is being developed for adults with familial adenomatous polyposis.
2017 Guidance Raised
Sucampo raised its guidance for full year 2017. The company now expects total revenue in the range of $250 million to $255 million (previously $220 million to $230 million). The Zacks Consensus Estimate for 2017 is $228.5 million.
The company increased its adjusted net income guidance to the range of $63 million to $68 million (previously $56 million to $66 million) and adjusted earnings in the range of $1.10 to $1.15 (previously $1.00 to $1.10).
Sucampo Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Sucampo Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Sucampo Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Sucampo carries a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the pharma sector includes Agenus Inc. AGEN and Exelixis, Inc. EXEL. Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Agenus’ loss estimates remained stable at $1.17 for 2017 and narrowed from $1.40 to $1.36 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 4.27%.
Exelixis’ earnings per share estimates remained stable at 26 cents for 2017 and increased from 63 cents to 64 cents for 2018 over the last 30 days. The company delivered positive earnings surprises in all the four trailing quarters with an average beat of 543.59%. The company’s shares are up 62.5% so far this year.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment